We serve Chemical Name:6-Iodo-1H-indazole CAS:261953-36-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:6-Iodo-1H-indazole
CAS.NO:261953-36-0
Synonyms:INDAZOLE,6-IODO;6-Iodoindazole;1H-Indazole, 6-iodo-;6-Iodo-1H-indazole;T56 BMNJ HI;1H-Indazole,6-iodo
Molecular Formula:C7H5IN2
Molecular Weight:244.033
HS Code:2933990090
Physical and Chemical Properties:
Melting point:207.0 to 211.0 °C
Boiling point:358.2±15.0 °C at 760 mmHg
Density:2.1±0.1 g/cm3
Index of Refraction:1.788
PSA:28.68000
Exact Mass:243.949738
LogP:2.85
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like INDAZOLE,6-IODO chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1H-Indazole,6-iodo physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-Iodo-1H-indazole Use and application,1H-Indazole, 6-iodo- technical grade,usp/ep/jp grade.
Related News: Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment. 6-Iodo-1H-indazole manufacturer CROS NT built up its own biometric services portfolio: clinical data management, biostatistics, statistical programming and medical writing, through a series of acquisitions in the early 2010s. In 2013, CROS NT established a foothold in the U.S. with its purchase of Stat-Tech Services, which had a presence in the medical devices sector. CROS NT followed up the next year with its buy of biometrics services provider MDSL International to broaden its U.K. branch. 6-Iodo-1H-indazole supplier This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician��s Choice plus Best Supportive Care. 6-Iodo-1H-indazole vendor Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment. 6-Iodo-1H-indazole factory This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician��s Choice plus Best Supportive Care.
